Armata Pharmaceuticals, Inc.
AMEX:ARMPBiotechnology
-$0.02 today
- Market cap
- $110.83M
- Beta
- 1.22
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$7.74
Volume 0.07M
Average 0.07M
Income Statement
Follow revenue through to earnings.
Revenue
$4.90M
FY 2025 · Annual
-5.2% YoYOperating Income
-$31.22M
FY 2025 · Annual
Net Income
-$173.80M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.47M | 5.51M | 4.53M | 5.17M | 4.9M |
| Cost of Revenue | 20.02M | 35.02M | 972K | 34.43M | 1.53M |
| Gross Profit | (15.54M) | (29.51M) | 3.56M | (29.25M) | 3.37M |
| Gross Margin | -347.4% | -535.7% | 78.5% | -565.4% | 68.8% |
| Research & Development | 20.02M | 35.02M | 33.77M | 34.43M | 23.72M |
| Selling, General & Admin | 8.28M | 7.44M | 10.68M | 13.18M | 12.41M |
| Operating Expenses | 8.28M | 7.44M | 44.45M | 13.18M | 34.6M |
| Depreciation & Amortization | 1.17M | 892K | 972K | 1.33M | 1.53M |
| EBITDA | (21.92M) | (36M) | (65.45M) | (6.85M) | (155.68M) |
| EBITDA Margin | -490.0% | -653.5% | -1445.1% | -132.4% | -3174.5% |
| Operating Income | (23.82M) | (36.95M) | (40.89M) | (42.44M) | (31.22M) |
| Operating Margin | -532.5% | -670.8% | -902.8% | -820.2% | -636.7% |
| Interest Income | 5K | 29K | 179K | 697K | 388K |
| Interest Expense | 64K | 29K | 2.63M | 10.74M | 16.59M |
| Other Income / Expenses | 667K | 29K | (28.16M) | 23.52M | (142.58M) |
| Income Before Tax | (23.16M) | (36.92M) | (69.05M) | (18.92M) | (173.8M) |
| Pre-Tax Margin | -517.5% | -670.2% | -1524.5% | -365.6% | -3544.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.16M) | (36.92M) | (69.05M) | (18.92M) | (173.8M) |
| Net Margin | -517.5% | -670.2% | -1524.5% | -365.6% | -3544.0% |
| EPS (Basic) | (0.96) | (1.08) | (1.91) | (0.52) | (4.80) |
| EPS (Diluted) | (0.96) | (1.08) | (1.91) | (0.52) | (4.80) |
| 24.1M | 34.29M | 36.08M | 36.16M | 36.24M | |
| 24.1M | 34.29M | 36.08M | 36.16M | 36.24M |
ARMP Earnings Waterfall · TTM
AMEX:ARMP · Revenue to Net Income
Key Ratios
Analysis
$3.0M of revenue converted into -$282.6M of net income for the selected period. Gross margin is 31.3% and net margin is -3842.6%, showing how much revenue survives after costs and taxes. EPS is $-7.77, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Sep 23, 2026 | |
| 8-K | Current report | Sep 14, 2026 | |
| 10-Q | Quarterly report | Aug 12, 2026 |
How much revenue does ARMP generate?
Armata Pharmaceuticals, Inc. (ARMP) reported $4.90M of revenue in fiscal 2025.
Is ARMP profitable?
Armata Pharmaceuticals, Inc. (ARMP) reported -$173.80M of net income, with a net margin of -3544.0%.
Continue the stock analysis
Jump to another research area for this company.